To find predictive factors of neovascular glaucoma (NVG) development in anterior segment neovascularization without glaucoma (ASNVWG) and poor visual outcomes in eyes that have already developed NVG.
Retrospective, clinical cohort studies METHODS: A retrospective chart review was performed on 106 eyes of 94 patients with ASNVWG and 245 eyes of 225 patients with NVG. Measured outcomes included the development of NVG at any time point of the disease for the ASNVWG arm, and a visual acuity of ≤ 20/200 at six months after initial presentation for the NVG arm.
25% of ASNVWG eyes progressed to NVG. Progression was associated with retinal vein occlusion (RVO) (p < 0.01), lower median presenting BCVA (p < 0.01), and concurrent traction retinal detachments (TRD) (p = 0.025). 68% of NVG eyes had a BCVA of ≤ 20/200 by six-month follow up, which was associated with RVO (p = 0.005), vitreous hemorrhage on presentation (p = 0.001), and no PRP treatments (p 20/200 vision at six months was associated with ≥ one PRP or intravitreal bevacizumab (IVB) treatment within one week of presentation or ≥ three PRP or IVB treatments overall (p <0.001).
RVO, presenting visual acuity, and concurrent TRD are risk factors for NVG in eyes with ASNVWG. In eyes with NVG, RVO and concurrent vitreous hemorrhage are risk factors for ≤ 20/200 vision at six months, whereas treatment with ≥ one PRP or IVB within one week of presentation, or ≥ three treatments of PRP or IVB within six months are protective.

Copyright © 2021 Elsevier Ltd. All rights reserved.